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Summary At the 2016 ASCO Annual Meeting, several
pertinent studies in the field of breast cancer were
presented. MA17.R was the first randomized phase III
trial to evaluate the prolongation of adjuvant aro-
matase-inhibitor (AI) therapy from 5 to 10 years;
while a significant reduction of disease-free survival
events was observed in the extended treatment group,
the absolute difference was relatively small and longer
endocrine therapy resulted in a higher fracture rate.
A combined analysis of three North American trials
emphasized the superiority of anthracycline contain-
ing adjuvant chemotherapy regimens compared with
docetaxel/cyclophosphamide (TC), while the PAN-
THER trial investigated dose-dense tailored adjuvant
treatment. In metastatic breast cancer, the main
interest was on cyclin-dependent kinase (CDK) 4/6
inhibitors. In PALOMA-2, the addition of palbociclib
to letrozole prolonged progression-free survival (PFS)
from 14.5 to 24.8 months resulting in the longest PFS
data ever reported in the first-line setting. A sub-
group analysis of premenopausal patients accrued
to PALOMA-3 indicated that in this patient subset,
ovarian function suppression plus fulvestrant and
palbociclib yielded results comparable to the post-
menopausal population. ESR1 mutations were an-
other focus of interest as these activating mutations
in the gene coding for the estrogen receptor alpha
apparently evolve under the selection pressure of AI
therapy.
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Extended adjuvant therapy
MA.17R was the first study evaluating the extension
of aromatase inhibitor (AI) therapy to 10 years [1]. Of
note, in hormone-receptor (HR)-positive breast can-
cer (BC), a prolonged albeit low recurrence risk has
been reported with the greatest risk observed in large,
node-positive and G3 tumors [2].
Patients were randomly assigned to receive 5 years
of letrozole or placebo after an initial 5 years of
letrozole either upfront or after 2–5 years of tamox-
ifen. At a median follow-up of 6.3 years, extended
AI therapy significantly improved 5-year disease-free-
survival (DFS) rates from 91 to 95% (HR = 0.61, p =
0.01) while no overall survival (OS) difference was re-
ported. Furthermore, a significant increase of fracture
rates was observed in the letrozole group. Regarding
quality-of-life (QoL), a substudy indicated that pro-
longation of endocrine therapy was not associated
with a significant overall QoL reduction but patients
in the letrozole group had significantly higher rates
of vasomotor symptoms and sexual dysfunction [3].
In summary, these data indicate that potential bene-
fits of extended endocrine therapy must be carefully
balanced with treatment tolerability and fracture risk.
Adjuvant chemotherapy
Blum et al. presented data from a combined analysis
of the NSABP B-46I, NSABP B-49, and USOR 06-090
studies (ABC trials) comparing six cycles of TC (do-
cetaxel/cyclophosphamide) with standard regimens
consisting of four cycles of taxane-based chemother-
apy followed by four cycles of AC (doxorubicin/
cyclophosphamide). The 3-year invasive DFS was
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91.7% in the TC group compared with 92.4% in pa-
tients with conventional therapy (HR = 1.202, p =
0.026). Therefore, TC was not non-inferior to con-
ventional therapy and performed even significantly
worse; as expected, a higher secondary leukemia rate
was reported in the anthracycline group. Still, these
data suggest that in the absence of contraindications,
anthracycline-containing regimens remain the stan-
dard of care [4]. PANTHER, also known as ABCSG-
25, was an open-label phase III study comparing
dose-dense tailored (ddt) with conventional adjuvant
chemotherapy [5]. Patients with node-positive or
high-risk node-negative BC were randomized to three
cycles of FEC100 followed by three cycles of docetaxel
100 mg/m² or EC (epirubicin/cyclophosphamide) × 4
followed by docetaxel × 4 given once every 2 weeks
(dose-dense) and dose adapted to the leukocyte nadir.
The main hypothesis tested in this study was the
assumption that chemotherapy dose adaption by
hematological toxicity may be more appropriate than
chemotherapy dosing by body surface area.
At a median follow-up of 5.3 years, fewer BC recur-
rence-free survival (BCRFS) events were recorded in
the ddt arm (HR = 0.79, 95% CI = 0.62–1.02, p = 0.064)
while QoL, on the other hand, was significantly worse
[6]. Of note, while ddt therapy was numerically supe-
rior, these patients received a greater overall number
of chemotherapy cycles, a dose-dense regimen, and
a regimen tailored by leukocyte nadir, making inter-
pretation of the results difficult.
Neoadjuvant therapy
The phase III ETNA trial asked whether nab-pacli-
taxel was superior to conventional paclitaxel when
used as part of preoperative chemotherapy [7]. Pa-
tients received four cycles of conventional paclitaxel
(90 mg/m²; days 1 + 8 + 15 of a 4-week cycle) or
nab-paclitaxel (125 mg/m²) followed by four cycles of
anthracycline-based therapy. In this study, relatively
low pCR rates of 18.1% (conventional paclitaxel) and
22.5% (nab-paclitaxel) were observed and no signifi-
cant difference between the two groups was recorded.
These data contradict the results of the GeparSepto
trial where nab-paclitaxel improved pCR rates sig-
nificantly [8]; of note, the regimen chosen in ETNA
may have caused this difference. While GeparSepto
used a standard regimen of paclitaxel or nab-pacli-
taxel weekly × 12, a regimen similar to the metastatic
setting was used in ETNA resulting in a lower taxane
dose density.
A British group reported DFS and OS outcomes of
the phase III ARTemis trial. The primary endpoint
analysis had already been published and a signif-
icantly higher pCR rate was observed when beva-
cizumab was added to neoadjuvant chemotherapy
(22% vs. 17%, p = 0.03) [9]. As shown at this year’s
ASCO Annual Meeting, this difference did not trans-
late into superior outcomes in terms of DFS and OS
[10]. In patients receiving chemotherapy alone, pCR
predicted a favorable long-term outcome (pCR 97%
vs. non-pCR 76%, p = 0.0006) while no such correla-
tion was seen in the bevacizumab group (pCR 84% vs.
non-pCR 74%, p = 0.19). These data, at first glance,
contradict the paradigm that pCR is a predictor of fa-
vorable long-term outcome in high-risk BC subtypes.
With bevacizumab-containing treatment, however,
this correlation seems to be less clear as bevacizumab
does not have any effect on micrometastases as indi-
cated by the negative adjuvant studies.
In the neoadjuvant treatment of HER2-positive BC,
the KRISTINE trial compared six cycles of T-DM1 plus
pertuzumabwith docetaxel, carboplatin, trastuzumab,
and pertuzumab (TCPH) [11]. Patients receiving
TCPH had a significantly higher pCR rate (55.7% vs.
44.4%, p = 0.0155) and this effect was even more
pronounced in non-luminal HER2-positive tumors.
Toxicity rates, on the other hand, were higher in the
TCPH arm as well.
While a lower pCR rate may be expected with
T-DM1 compared with conventional therapy, pCR
rates in the KRISTINE trial compare well to the re-
sults from the luminal B/HER2-positive cohort of
the ADAPT trials where T-DM1 alone yielded a pCR
rate of 41% [12]. This indicates that – similar to the
metastatic setting – T-DM1 has considerable activity
that cannot be further improved by the combination
of pertuzumab [13].
Metastatic breast cancer
The main interest in the field of metastatic BC was in
cyclin-dependent kinase (CDK) 4/6 inhibitors, a class
of orally available drugs blocking cell-cycle progres-
sion.
The phase III PALOMA-2 trial allocated 666 patients
with HR-positive/HER2-negative disease to letrozole
plus the CDK 4/6 inhibitor palbociclib or letrozole
plus placebo [14]. Patients with resistance to AIs (de-
fined as progression on or within 12 months of adju-
vant AI therapy) were excluded. Addition of palboci-
clib to endocrine therapy improved progression-free
survival (PFS) from 14.5 to 24.8 months (HR = 0.58,
95% CI = 0.46–0.72, p < 0.000001), resulting in the
longest PFS data ever reported in the first-line setting.
Treatment was well tolerated with neutropenia being
the most common side effect (79.5% vs. 6.3%); febrile
neutropenia, however, was rare (2.5% in the palboci-
clib group). While it is currently not clear whether
patients progressing on palbociclib will respond to
further endocrine therapy, it appears that this rele-
vant prolongation of DFS will ultimately define a novel
first-line treatment standard.
In contrast to PALOMA-2, pretreated women were
included in the PALOMA-3 trial and randomized to
fulvestrant plus/minus palbociclib. The inclusion of
premenopausal women who received additional ovar-
ian function suppression was allowed; in this subset,
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the addition of palbociclib increased PFS from 5.6 to
9.5 months, suggesting that treatment activity in pre-
menopausal subjects was comparable to the general
study population [15].
A correlative study of PALOMA-3 investigated the
prognostic and predictive role of activating ESR1 mu-
tations, a gene coding for the estrogen receptor alpha
[16]. ESR1 mutations were present in 26.8% of all sam-
ples and were only recorded in patients with prior AI
exposure, leading to the hypothesis that ESR1 muta-
tions develop under the selection pressure of AI ther-
apy. In PALOMA-3, the presence of the ESR1 mutation
was predictive of shorter PFS but the activity of pal-
bociclib plus fulvestrant was independent of mutation
status.
Finally, the development of immunotherapy was
clearly delayed in BC. Current studies are focusing on
the investigation of immune-checkpoint modulators
in TN disease. In a phase Ib study, patients with
metastatic TN BC received a combination of nab-pa-
clitaxel plus atezolizumab, a humanized monoclonal
antibody targeting PD-L1 [17]. The safety cohort of
this study consisted of 32 patients, while 24 sub-
jects were evaluable for response. The grade 3/4
neutropenia rate was 41%, but no dose-limiting tox-
icity was recorded. Of note, acitivity was promising
with high response rates across all treatment lines
independently of PD-L1 expression. Owing to these
favorable outcomes, a corresponding phase III trial
(IMPASSION; NCT02425891) is currently ongoing.
Conclusion
In summary, the results from several relevant trials
were presented at the 2016 ASCO Annual Meeting;
of note, the results of the PALOMA-2 trial may prove
practice changing.
Take-home message MA17.R indicated that the ex-
tension of AI therapy to 10 years was associated with
a significant reduction of DFS events, but this differ-
ence was modest in absolute numbers and fracture
rates were significantly increased. A combined anal-
ysis showed that conventional anthracycline-contain-
ing regimens were superior to six cycles of the an-
thracycline-free TC regimen. In the PANTHER study,
ddt chemotherapy was compared with conventionally
dosed FEC-Doc. While a numerical improvement was
observed in the ddt arm, this difference did not reach
statistical significance and QoL was significantly lower
in the experimental group.
In metastatic BC, the PALOMA-2 trial showed that
the addition of palbociclib to first-line letrozole re-
sulted in a clinically relevant prolongation of PFS from
14.5 to 24.8 months. Besides CDK 4/6 inhibitors, the
prognostic and predictive role of ESR1 mutations was
another focus of interest and currently available data
suggest that ESR1 mutations may evolve under the
selection pressure of AI therapy. Finally, the combi-
nation of chemotherapy and PD-L1 inhibitors holds
promise in metastatic TN disease.
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